Worsening skin damage in patients with cutaneous lupus erythematosus may predict development of systemic lupus erythematosus

Walocko, Frances M.; Black, Samantha; Anderson, Scott R.; Li, Xilong; Adams‐Huet, Beverley; Chong, Benjamin F.

doi:10.1016/j.jaad.2020.05.020

Cited by 5 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tee et al, using a pair‐wise as well as a network meta‐analysis, analyzed six randomized controlled trials of either acitretin or nicotinamide for systemic chemoprevention in transplant patients against their developing new squamous cell, basal cell, and AKs. Both acitretin and nicotinamide were efficacious when administered orally, with no significant difference between their degree of efficacy 7 …”

Section: Chemoprevention Of Aksmentioning

confidence: 93%

Actinic keratoses: The latest in therapy

Berman

2021

Dermatological Reviews

View full text Add to dashboard Cite

The following is a review of the pathogenesis and natural history of actinic keratoses, their progression to squamous cell carcinoma, and recent findings and insights into the mechanisms of action of chemopreventative and field therapeutic agents for actinic keratoses are highlighted. Oral nicotinamide appears to be a safe and tolerable chemopreventative agent although its effectiveness requires continued use. Tirbanibulin ointment 1% is novel in its proposed mechanism of action and requires the shortest period of treatment of currently US Food and Drug Administration-approved, topically applied field therapies for actinic keratoses.

show abstract

Section: Chemoprevention Of Aksmentioning

confidence: 93%

Actinic keratoses: The latest in therapy

Berman

2021

Dermatological Reviews

View full text Add to dashboard Cite

show abstract

“…57 patients remained CLE (CLE-only) while 12 CLE patients progressed to SLE (CLE to SLE). CLE to SLE patients had more likely to have immunologic disorder than CLE-only patients; however, individual autoantibodies and laboratory abnormalities were not significantly higher in these patients(27). In a retrospective study of 40 children with DLE, six had SLE concurrently with their DLE diagnosis while nine progressed from DLE to SLE.…”

mentioning

confidence: 91%

Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus

2021

Self Cite

View full text Add to dashboard Cite

Cutaneous lupus erythematosus (CLE) is a connective tissue disease with varying presentations, and clinical sequelae including itching, dyspigmentation, and scarring. CLE can occur as its own entity or in conjunction with systemic disease, known as systemic lupus erythematosus (SLE). Because CLE is clinically diverse, identification of a biomarker may help not only facilitate early diagnosis and management but also identify individuals at risk for poor prognosis and development of SLE. While potential biomarkers in SLE have been extensively studied, few biomarkers for CLE have been identified and incorporated into clinical practice. Anti-SS-A antibody is a commonly used biomarker for diagnosis of subacute CLE patients.Type I interferon-related proteins such as MxA and guanylate binding protein-1 (GBP-1) and chemokines such as CXCR3, CXCL9, and CXCL10 have been identified as biomarkers that may support diagnosis and track disease activity. First-line oral treatment for CLE currently consists of anti-malarials such as hydroxychloroquine (HCQ), chloroquine (CQ), and quinacrine (QC). Studies have found that an increased myeloid dendritic cell population with higher TNF-α expression may be predictive of poor treatment response to HCQ in CLE patients. Autoantibodies against nuclear antigens (e.g., anti-double-stranded DNA and anti-Smith antibodies) and elevated erythrocyte sedimentation rate have been more commonly found in CLE patients progressing to SLE than those who have not. This review aims to summarize previous and emerging biomarkers for CLE patients.

show abstract

Lupus Erythematosus and Antiphospholipid Syndrome

Dutz,

Khosravi‐Hafshejani

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

Lupus erythematosus is an autoimmune disease that commonly affects the skin, and may present with cutaneous only disease. This chapter reviews the forms of cutaneous lupus‐specific skin disease (discoid lupus, subacute cutaneous lupus, lupus tumidus and acute cutaneous lupus), their clinical features, pathogenesis and treatment. A review of systemic lupus erythematosus is also provided with a discussion of diagnosis, clinical features, cutaneous aspects and treatment, germane for the dermatologist. Clinical features of neonatal lupus erythematosus and the antiphospholipid antibody syndrome, more commonly seen in systemic lupus erythematosus kindreds, are also discussed.

show abstract

Worsening skin damage in patients with cutaneous lupus erythematosus may predict development of systemic lupus erythematosus

Abstract: Funding sources: None. Conflicts of interest: None disclosed. IRB approval status: Reviewed and approved by medical ethical review committee of Maastricht University Medical Centre1 (METC 16-4-172).

Cited by 5 publications

References 5 publications

Actinic keratoses: The latest in therapy

Actinic keratoses: The latest in therapy

Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus

Lupus Erythematosus and Antiphospholipid Syndrome

Contact Info

Product

Resources

About